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Background: Type 2A protein phosphatase (PP2A) enzymes are serine/threonine phosphatases which comprise a
scaﬀold A subunit, a regulatory B subunit and a catalytic C subunit, and have been implicated in the depho-
sphorylation of multiple cardiac phosphoproteins. B subunits determine subcellular targeting, substrate speci-
ﬁcity and catalytic activity, and can themselves be regulated by post-translational modiﬁcations. We explored
potential β-adrenergic regulation of PP2A in cardiomyocytes through phosphorylation of the regulatory B
subunit isoform B56δ.
Methods and results: Phosphate aﬃnity SDS-PAGE and immunoblot analysis revealed increased phosphorylation
of B56δ in adult rat ventricular myocytes (ARVM) exposed to the β-adrenergic receptor (βAR) agonist iso-
prenaline (ISO). Phosphorylation of B56δ occurred at S573, primarily through stimulation of the β1AR subtype,
and was dependent on PKA activity. The functional role of the phosphorylation was explored in ARVM trans-
duced with adenoviruses expressing wild type (WT) or non-phosphorylatable (S573A) B56δ, fused to GFP at the
N-terminus. C subunit expression was increased in ARVM expressing GFP-B56δ-WT or GFP-B56δ-S573A, both of
which co-immunoprecipitated with endogenous C and A subunits. PP2A activity in cell lysates was increased in
response to ISO in ARVM expressing GFP-B56δ-WT but not GFP-B56δ-S573A. Immunoblot analysis of the
phosphoproteome in ARVM expressing GFP-B56δ-WT or GFP-B56δ-S573A with antibodies detecting (i)
phospho-serine/threonine residues in distinct kinase substrate motifs or (ii) speciﬁc phosphorylated residues of
functional importance in selected proteins revealed a comparable phosphorylation proﬁle in the absence or
presence of ISO stimulation.
Conclusions: In cardiomyocytes, βAR stimulation induces PKA-mediated phosphorylation of the PP2A regulatory
subunit isoform B56δ at S573, which increases associated PP2A catalytic activity. This is likely to regulate the
phosphorylation status of speciﬁc B56δ-PP2A substrates, which remain to be identiﬁed.
1. Introduction
Type 2A protein phosphatase (PP2A) holoenzymes are present in
most cell types, including cardiac myocytes, where they depho-
sphorylate phospho-serine (Ser, S) and phospho-threonine (Thr, T) re-
sidues in proteins. PP2A holoenzymes comprise a 65-kDa scaﬀold
(PP2AA or A) subunit, a 36-kDa catalytic (PP2AC or C) subunit and a
regulatory (PP2AB or B) subunit of variable molecular weight that de-
termines subcellular targeting, substrate speciﬁcity and catalytic ac-
tivity [1–4]. The importance of B subunits and regulated catalytic ac-
tivity in the heart is highlighted by the dilated cardiomyopathy
phenotype of mice expressing a mutant A subunit that binds the C but
not the B subunit [5], and by the impaired cardiac function of mice with
cardiomyocyte-speciﬁc overexpression of the C subunit [6].
B subunits are classiﬁed into three families, PR55/B, PR61/B′ and
PR72/B″. The largest of these is the PR61/B′ family, which is commonly
referred to as the B56 family and comprises α, β, γ, δ and ε isoforms [2].
Conserved sequences residing in the central domain of B56 isoforms
enable association with the AC dimer, whilst unique sequences at the N-
and C-terminals determine isoform-speciﬁc functions [7,8]. Regarding
the role of individual isoforms in the heart in vivo, studies in mice with
global deletion [9] or cardiac-speciﬁc overexpression [10] of B56α
https://doi.org/10.1016/j.yjmcc.2017.12.016
Received 2 September 2017; Received in revised form 19 December 2017; Accepted 29 December 2017
⁎ Corresponding author at: School of Cardiovascular Medicine and Sciences, King's College London, The Rayne Institute, St Thomas' Hospital, Westminster Bridge Road, London SE1
7EH, United Kingdom.
E-mail address: metin.avkiran@kcl.ac.uk (M. Avkiran).
Abbreviations: ARVM, adult rat ventricular myocytes; CaMKII, calcium/calmodulin-dependent kinase II; cMyBP-C, cardiac myosin binding protein-C; cTnI, cardiac troponin I; I-1,
inhibitor of protein phosphatase-1; ISO, isoprenaline; KO, knock out; MOI, multiplicity of infection; BNZ, N6-benzoyl-cAMP; PLB, phospholamban; PKA, protein kinase A; Ser, S, serine;
Thr, T, threonine; PP1, type 1 phosphatase; PP2A, type 2A protein phosphatase; WT, wild type; βAR, β-Adrenergic receptor
Journal of Molecular and Cellular Cardiology 115 (2018) 20–31
Available online 30 December 2017
0022-2828/ © 2017 Published by Elsevier Ltd.
T
indicate that this B subunit regulates contractility, potentially through
phospho-regulation of proteins involved in excitation-contraction (EC)
coupling. Studies in mice with global deletion of B56γ indicate that this
isoform regulates cardiac development [11].
The focus of this study is B56δ. The gene encoding B56δ in humans
(PPP2R5D) is localized in chromosome region 6p21.1 and gives rise to
three splice variants that diﬀer at the N-terminus [12–14]. With 602
amino acids and a predicted molecular weight of 70-kDa, δ1 is the
largest splice variant. Relative to this splice variant, δ2 and δ3 lack
amino acids 84-115 and 1-115, respectively. Studies in vitro have
shown that the activity of B56δ-PP2A can be increased by protein ki-
nase A (PKA), through phosphorylation of B56δ at S60, S75, S88 and
S573 [15–17]. In non-cardiac cells, B56δ phosphorylation at S573 is
necessary for increased B56δ-PP2A activity and is induced by G protein-
coupled receptors that signal via the Gs-adenylate cyclase-cAMP-PKA
pathway such as dopamine D1 and luteinizing hormone receptors
[16,18].
Little information is available regarding B56δ expression, regulation
and function in the heart. Mice lacking B56δ were the ﬁrst mice with
targeted disruption of a B56 subunit to be studied; however, their
cardiac phenotype was not studied [19]. More recently, DeGrande et al.
[20] have shown that B56δ protein is expressed in mammalian heart
chambers, and that its levels are increased in dog hearts with ischemic
or non-ischemic heart failure.
In view of the importance of the Gs-adenylate cyclase-cAMP-PKA
pathway in mediating cardiomyocyte responses to β-adrenergic re-
ceptor (βAR) stimulation [21,22], we have explored potential β-AR-
mediated regulation and role of B56δ phosphorylation in adult rat
ventricular myocytes (ARVM). We have found that (i) B56δ is phos-
phorylated at S573 following the acute stimulation of βARs, (ii) this
response occurs primarily downstream of the β1AR and is mediated by
PKA, and (iii) B56δ phosphorylation at S573 is necessary for βAR-
mediated stimulation of PP2A activity.
2. Materials and methods
2.1. Materials
cTnI, pS23/24 cTnI, PP2AC, PLB and phospho-S/T kinase substrate
antibodies were from Cell Signaling Technology (2002, 4002, 2038,
8495 and 9920, respectively). GAPDH, H2B and B56γ antibodies were
from Abcam (Ab9482, Ab1790-100 and Ab94633, respectively). B56α
and B56δ antibodies were from BD Biosciences (610615) and Bethyl
(A301-100A), respectively. PP2AA and B55α antibodies were from
Santa Cruz (sc-74580 and sc-81606, respectively). GFP and α-Actinin
antibodies were from Roche (11814460001) and Sigma (A7732), re-
spectively. pS16 PLB and pS282 cMyBP-C antibodies were from Badrilla
(A010-12AP) and Enzo Life Sciences (ALX-215-057-R050), respectively.
The cMyBP-C antibody was a kind gift from Professor Mathias Gautel
[23]. pS273 and pS302 cMyBP-C antibodies were a kind gift from Dr.
Jeﬀrey Robbins [24,25]. The pS573 B56δ antibody was a kind gift from
Professor Angus Nairn [16]. Cy3- and Cy5-conjugated secondary anti-
bodies were from Jackson ImmunoResearch (115165146 and
111175144, respectively). Isoprenaline (ISO), propranolol (PRO), CGP-
20712A (CGP) and ICI 118,551 (ICI) were from Sigma (I5627, P0084,
C231 and I127, respectively). H89, myristoylated PKA inhibitor 14-22
amide (PKI), N6-benzoyl cAMP (BNZ), and okadaic acid were from
Calbiochem (371962, 476485, 116802 and 495609, respectively). The
pEGFP-C1 vector encoding PPP2R5D and cardiac tissue from littermate
B56δ knock out (KO) and WT mice were kind gifts from Professor
Veerle Janssens [19]. Adult male Wistar rats (300–324 g) were from
Harlan Laboratories (UK).
2.2. Construction of adenoviral vectors
To replace S573 with alanine, a single point mutation was
introduced into human PPP2R5D in a pEGFP-C1 vector using the
QuikChange II Site-Directed Mutagenesis Kit (Stratagene). The adeno-
viral vectors expressing wild type (WT) B56δ (AdV.GFP-B56δ-WT) and
mutated (S573A) B56δ (AdV.GFP-B56δ-S573A) were constructed using
the AdEasy system [26]. In brief, GFP-B56δ cDNA was subcloned into
pShuttle-CMV (Stratagene) and homologous recombination of this with
pAdEasy-1 (Stratagene) was performed in bacterial cells. Adenoviruses
were ampliﬁed in HEK293 cells and puriﬁed using a cesium chloride
density gradient in combination with ultracentrifugation. The in-
fectious titer of the puriﬁed adenoviruses was determined in tissue
culture infectivity dose 50 assays [27].
2.3. Isolation, culture and adenoviral transduction of ARVM
ARVM were isolated from the hearts of adult male Wistar rats by
collagenase-based enzymatic digestion, as previously described
[28,29]. Isolated cells were resuspended in Hank's M199 medium
supplemented with 2 mM L-creatine, 5 mM carnitine, 5 mM taurine and
100 IU/ml penicillin/streptomycin, and were cultured in plastic 6-well
plates pre-coated with laminin. Cells were maintained in a humidiﬁed
incubator (5% CO2, 37 °C) for 2 h after which, the medium was re-
placed with fresh medium and cells were incubated overnight. Where
indicated, cells were transduced with adenoviruses 2 h post-plating.
AdV.GFP was used at MOI 30. AdV.GFP-B56δ-WT and AdV.GFP-B56δ-
S573A were both used at MOI 100.
2.4. Pharmacological treatment of ARVM
Unless otherwise stated, ARVM were incubated with vehicle or
10 nM ISO for 10 min. PRO (100 nM), CGP (100 nM), ICI (100 nM) or
vehicle was added to the culture medium 10 min before ISO stimula-
tion. H89 (10 μM), PKI (10 μM) or vehicle was added 30 min before ISO
stimulation. Cells were exposed to BNZ (500 μM) or vehicle for 30 min,
and to OA (0.1 or 1 μM) or vehicle for 60 min. Experiments were per-
formed at 37 °C.
2.5. Subcellular fractionation of ARVM
The subcellular fractionation method was adapted from methods
described in previous publications [29,30]. In brief, cells were har-
vested in ice-cold lysis buﬀer containing: 50 mM Tris (pH 7.5), 5 mM
EGTA, 2 mM EDTA, 100 mM NaF, 1% (v/v) Triton-X100 and complete
mini protease inhibitor (Roche). Cell lysates were incubated on ice for
5 min after which, they were centrifuged at 14,000g for 30 min at 4 °C.
Proteins in the soluble fraction (supernatant) were denatured in 3X
Laemmli sample buﬀer. Proteins in the insoluble fraction (pellet) were
resuspended in 1X Laemmli sample buﬀer.
2.6. SDS-PAGE and immunoblot analysis
Heat-denatured protein samples were resolved on Tris-glycine SDS-
PAGE gels and transferred to PVDF membranes. Membranes were
blocked in Tris-buﬀered saline with 0.1% Tween-20 (TBST) and 5% (w/
v) non-fat milk. Incubation with primary antibodies was performed
overnight at 4 °C and incubation with secondary antibodies was per-
formed for 2 h at room temperature. Protein bands were visualized on
chemiluminescence ﬁlm following incubation of the membranes with
ECL Western Blotting Detection Reagents (GE Healthcare). Signal in-
tensity was quantiﬁed on a calibrated GS-800 densitometer (Bio-Rad).
Phosphate aﬃnity (PhosTag) SDS-PAGE was performed on Tris-glycine
gels containing 50 μM acrylamide-pendent PhosTag™ and 100 μM
MnCl2. Prior to transfer of proteins to PVDF membranes, gels were
incubated 15 min in transfer buﬀer containing 1 mM EDTA then 15 min
in transfer buﬀer alone.
A. Ranieri et al. Journal of Molecular and Cellular Cardiology 115 (2018) 20–31
21
2.7. Immunolabeling and imaging of ARVM
ARVM were prepared for imaging on a confocal ﬂorescence mi-
croscope as previously described [31]. Unless otherwise stated, in-
cubations were performed at room temperature. In brief, cells were
incubated with (i) 4% paraformaldehyde for 10 min, (ii) 0.2% (v/v)
Triton-X100 for 5 min, and (iii) 5% normal goat serum for 20 min. In-
cubation with primary antibodies (or control IgG) was performed
overnight at 4 °C. Incubation with Cy3- and Cy5-conjugated secondary
antibodies was performed for 3 h. Cells were overlaid with coverslips in
a mounting media containing the anti-fading reagent n-propyl gallate
[32]. Immunolabeled cells were imaged on a Leica TCS SP5 confocal
microscope equipped with a UV-diode, an argon laser and a helium-
neon laser, as previously described [29,31].
2.8. Immunoprecipitation of GFP, GFP-B56δ-WT and GFP-B56δ-S573A
GFP, GFP-B56δ-WT and GFP-B56δ-S573A were immunoprecipitated
from ARVM lysates using a GFP antibody. Cells were harvested in ice-
cold lysis buﬀer containing: 50 mM Tris (pH 8), 138 mM NaCl, 27 mM
KCl, 1% (v/v) Triton-X100 and complete mini protease inhibitor. The
cleared lysate containing 500 μg of protein was incubated with anti-
GFP (4 μg) over-night at 4 °C. Immunocomplexes were collected using
Protein G beads. After three washes in lysis buﬀer, these were re-
suspended in Laemmli buﬀer.
2.9. Measurement of protein phosphatase activity
Protein phosphatase activity was determined using the SensoLyte
pNPP Protein Phosphatase Assay kit (AnaSpec), as recommended by the
manufacturer. Cells expressing heterologous proteins were washed in
phosphate-buﬀered saline and harvested in 1X lysis buﬀer with added
1% (v/v) Triton-X100 and protease inhibitors. Master mixes of whole
cell lysates in assay buﬀer (40 mM Tris (pH 8.4), 34 mM MgCl2, 4 mM
EDTA and 4 mM DTT) were prepared on ice. Incubation with 5 nM
okadaic acid or DMSO was performed for 10 min. Assays were per-
formed in triplicates, in wells of 96-well plates. Individual wells con-
tained 10 μg of protein in 50 μl of master mix and 50 μl of pNPP solu-
tion. Absorbance at 405 nm was determined in a plate reader pre-
heated to 30 °C. Measurements were recorded at 5 min intervals, for a
total of 30 min. The amount of pNP produced was determined using the
equation c = A÷ (ɛ× l), where c is the concentration of pNP, A is the
optical absorbance of pNP at 405 nm, ɛ is the molar extinction coeﬃ-
cient of pNP (18,000 M−1 cm−1) and l is the path length.
2.10. Mouse pressure overload hypertrophy model
Transverse aortic constriction (TAC) surgery was performed in adult
mice by Professor Brian Cooley (Animal Surgery Core Laboratory,
McAllister Heart Institute, UNC School of Medicine). Male C57Bl/6
mice at 9 weeks of age were anaesthetised by intraperitoneal injection
Fig. 1. ISO-induced B56δ phosphorylation in ARVM. A.
Amino acids at the C-terminus of human (UniProt entry
Q14738), rat (UniProt entry Q499R1) and mouse (UniProt
entry Q91V89) B56δ isoforms. Asterisks denote identical
amino acids; phosphorylatable serine residues (S573 in the
human, S593 in the rat and S565 in the mouse isoform) are
in bold. The polyclonal B56δ antibody is raised against a
sequence of amino acids between amino acids 552 and 602
of the human isoform. The phospho-S573 B56δ antibody is
raised against a phospho-peptide comprising the under-
lined residues. B. Lysates of ARVM exposed to vehicle
(VEH) or isoprenaline (ISO) were subjected to phosphate
aﬃnity (PhosTag) SDS-PAGE and standard SDS-PAGE.
Immunoblot analysis was performed with a B56δ antibody.
C. ARVM were exposed to 1 nM, 10 nM or 100 nM ISO.
Figure shows representative immunoblots and quantitative
data (mean ± SEM) for B56δ phosphorylation at S573.
*P < 0.05 vs 0 nM ISO, ✝P < 0.05 vs 1 nM ISO,
☨P < 0.05 vs 10 nM ISO (n= 3). D. ARVM were exposed
to 10 nM ISO for 2, 5, 10, 30 or 60 min. Figure shows re-
presentative immunoblots and quantitative data
(mean ± SEM) for B56δ phosphorylation at S573.
*P < 0.05 vs 0 min (n= 3).
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of 100 mg/kg ketamine and 15 mg/ml xylazine. Constriction of the
aortic arch was achieved by ligation of the aorta with 6-0 silk, using a
27.5-gauge spacer. Sham animals were subjected to the same surgical
procedure, with no constrictive suture. Hearts were harvested 7 days
after the surgical procedure and frozen in liquid N2 for subsequent
analysis.
2.11. Data analysis
Quantitative data are presented as mean ± SEM. Diﬀerences be-
tween groups were analysed by unpaired t-test, or One-Way ANOVA
followed by Tukey's multiple comparisons test. P < 0.05 was con-
sidered signiﬁcant. In ﬁgure legends, n indicates the number of in-
dependent experiments.
3. Results
3.1. The eﬀect of ISO on phosphorylation of B56δ in ARVM
To explore the eﬀect of βAR stimulation on B56δ phosphorylation in
cardiomyocytes, cell lysates from unstimulated and ISO-stimulated
ARVM were resolved by standard- and PhosTag SDS-PAGE.
Immunoblot analysis was performed with a polyclonal antibody raised
against a peptide sequence at the C-terminus (aa 552-602) of human
B56δ, which is conserved in the rat and mouse protein (Fig. 1A). When
proteins were resolved by standard SDS-PAGE, a single protein mi-
grating at ~70-kDa was detected in all samples, indicating that ARVM
express only the δ1 splice variant (Fig. 1B, left panel). When PhosTag
SDS-PAGE was used, an additional B56δ band that migrated more
slowly was detected in ISO-stimulated cells, indicating increased B56δ
phosphorylation (Fig. 1B, right panel). Further studies of the speciﬁc
site of phosphorylation were guided by the evidence that in primary
non-cardiac cells phosphorylation occurs at S573 [16]. As indicated in
Fig. 1A, S573 in human B56δ corresponds to S593 in the rat protein and
S565 in the mouse protein. To determine phosphorylation of this con-
served residue in ARVM, we used a previously described phospho-
speciﬁc antibody that recognizes human B56δ phosphorylated at S573
(the target phospho-motif is underlined in Fig. 1A) [16]. ISO induced a
concentration-dependent increase in S573 phosphorylation that was
signiﬁcant at concentrations≥ 10 nM (Fig. 1C). With 10 nM ISO,
maximum phosphorylation was achieved within 2 min of stimulation
and the response was sustained for at least 60 min (Fig. 1D). These data
indicate that in ARVM stimulation of βARs induces rapid and robust
phosphorylation of B56δ at S573. Conﬁrming the speciﬁcity of the total
and phospho-S573 B56δ antibodies, the protein detected by these an-
tibodies at ~70-kDa in ARVM and WT mouse heart was not detected in
B56δ KO19 mouse heart (Supplementary Fig. 1).
3.2. The role of βAR subtypes and PKA in ISO-induced phosphorylation of
B56δ
We next investigated the signaling mechanisms that underlie ISO-
induced B56δ phosphorylation at S573. The response was blocked by
propranolol, a non-selective βAR antagonist, conﬁrming a βAR-medi-
ated mechanism (Fig. 2A). To determine the contributions of individual
βAR subtypes, we used CGP 20712A (CGP) and ICI 118,551 (ICI) to
selectively block β1 or β2ARs, respectively. ISO-induced B56δ phos-
phorylation at S573 was abolished by CGP and partially attenuated by
ICI (Fig. 2A). Reﬂecting the established βAR subtype selectivity of the
antagonists [33,34], phosphorylation of cardiac troponin I (cTnI) at
S23/24, the sites phosphorylated by PKA downstream of β1ARs [35],
was abolished by CGP but was not aﬀected by ICI (Fig. 2A). Guided by
the evidence that PKA phosphorylates B56δ at S573 in non-cardiac cells
[16], we determined the role of PKA in cardiac B56δ phosphorylation at
this site. To inhibit PKA in ARVM, we incubated cells with the ATP
binding-site competitor H89 or the inhibitory peptide PKI before
stimulation with ISO. The ISO-induced increase in B56δ S573 phos-
phorylation was abolished by H89 (Fig. 2B, left panel) and signiﬁcantly
attenuated by PKI (Fig. 2B, right panel). Importantly, H89 and PKI in-
hibited the ISO-induced increase in cTnI phosphorylation to a similar
extent, indicating that the observed reductions in B56δ phosphorylation
reﬂected the extent of PKA inhibition achieved by the inhibitors. In
complementary studies, we used the PKA-selective analogue of cAMP,
N6-benzoyl-cAMP (BNZ) [36], to determine the eﬀect of direct PKA
activation on B56δ S573 phosphorylation. The increase in S573 phos-
phorylation induced by BNZ was comparable to that induced by 10 nM
ISO (Fig. 2C). Together, these data suggest that activation of PKA is
both necessary and suﬃcient for B56δ phosphorylation at S573 in
ARVM.
3.3. Subcellular distribution of B56δ in ARVM
We have shown previously that ISO stimulation in ARVM induces a
change in the subcellular distribution of a diﬀerent B56 isoform, B56α
[29]. To determine if ISO alters subcellular distribution of B56δ, we
used ﬂuorescence microscopy to visualise the immunolabeled protein in
intact myocytes. B56δ was found throughout the cytosol and was pre-
sent in nuclei, in both unstimulated and ISO-stimulated cells (Fig. 3A).
The speciﬁcity of the rabbit B56δ antibody was conﬁrmed by in-
cubating cells with an equivalent concentration of non-immune rabbit
IgG (Supplementary Fig. 2). In complementary experiments, we de-
termined the distribution of B56δ in soluble and insoluble compart-
ments of fractionated cells (Fig. 3B). The purity of the soluble and in-
soluble fractions was determined by immunoblot analysis of proteins
with known subcellular compartmentalization, with GAPDH (a cyto-
solic enzyme) selected as the marker for the soluble fraction and histone
2B (H2B, a nuclear, DNA-bound protein) and cTnI (a myoﬁlament
protein) selected as markers for the insoluble fraction. Although shown
to be present in the nuclei of intact cells, B56δ was detected primarily in
the soluble subcellular fraction, suggesting labile nuclear interactions.
Furthermore, the abundance of B56δ in the soluble and insoluble
fraction was unchanged in response to ISO. In contrast, and consistent
with our previous work [29], B56α abundance in the insoluble fraction
was reduced following ISO stimulation. Together, these data suggest
that increased phosphorylation of B56δ at S573 does not alter its sub-
cellular distribution in ARVM.
3.4. Adenoviral expression of GFP-B56δ-WT and GFP-B56δ-S573A in
ARVM
To study the functional importance of B56δ phosphorylation at
S573, we constructed adenoviral vectors for heterologous expression of
GFP-tagged WT or non-phosphorylatable (S573A) B56δ (AdV.GFP-
B56δ-WT and AdV.GFP-B56δ-S573A, respectively) in ARVM. Control
cells were transduced with an adenovirus that expresses GFP alone
(AdV.GFP). Comparable GFP protein expression was achieved following
18 h incubation with AdV.GFP at multiplicity of infection (MOI) 30 and
AdV. GFP-B56δ-WT or AdV.GFP-B56δ-S573A at MOI 100
(Supplementary Fig. 3A). Immunoblot analysis of the same samples
with the B56δ antibody conﬁrmed comparable expression of GFP-B56δ-
WT and GFP-B56δ-S573A, and showed that, relative to cells expressing
GFP alone, expression of endogenous B56δ was unchanged
(Supplementary Fig. 3B). To further characterize the adenoviral vec-
tors, we determined protein levels of endogenous PP2A subunits in
transduced cells. Expression of GFP-B56δ-WT and GFP-B56δ-S573A was
associated with increased expression of C subunits, but no change in the
expression of A subunits. Expression of other B subunit isoforms (B55α,
B56α and B56γ) was also unchanged (Fig. 4A). To determine whether
GFP-B56δ-WT and GFP-B56δ-S573A were incorporated into PP2A ho-
loenzymes, protein complexes were immunoprecipitated from lysates of
transduced cells using a GFP antibody and the resulting samples were
subjected to SDS-PAGE and immunoblot analysis. Both A and C
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subunits were detected (in comparable abundance) in samples from
cells expressing GFP-B56δ-WT and GFP-B56δ-S573A, suggesting that
the GFP-tagged B56δ variants were indeed incorporated into PP2A
holoenzymes within ARVM (Fig. 4B). To characterize the phosphor-
ylation status of GFP-B56δ-WT and GFP-B56δ-S573A in ARVM, im-
munoblot analysis of unstimulated and ISO-stimulated cells was per-
formed with the phospho-S573 B56δ antibody. Basal and ISO-induced
phosphorylation of S573 was detected in GFP-B56δ-WT but not GFP-
B56δ-S573A, conﬁrming loss of the phosphorylatable residue in the
latter protein (Fig. 4C). ISO-induced phosphorylation of S573 in en-
dogenous B56δ was detected simultaneously and was comparable in all
groups (Fig. 4C).
In the HEK293 cell line, PKA activation has been reported to induce
B56δ phosphorylation not just at S573 but also at S88, albeit to a much
smaller extent [16]. In human B56δ, both S573 and S88 are preceded
by arginine (R) residues at the −2 and −3 positions, forming optimal
PKA substrate motifs (Supplementary Fig. 4A). To determine if S573 is
the only site that is phosphorylated in heterologously expressed human
B56δ in ARVM, GFP-B56δ-WT or GFP-B56δ-S573A immunoprecipitated
from lysates of unstimulated and ISO-stimulated cells was subjected to
immunoblot analysis with a phospho-speciﬁc antibody that detects
phospho-S/T (S/T) residues in the RRXS/T motif. This antibody de-
tected basal S/T phosphorylation in GFP-B56δ-WT and the signal was
markedly increased following ISO stimulation (Supplementary Fig. 4B).
In contrast, the antibody did not detect GFP-B56δ-S573A in the absence
or presence of ISO stimulation (Supplementary Fig. 4B), indicating that
Fig. 2. The role of βAR subtypes and PKA in ISO-induced
B56δ phosphorylation. A. ARVM were exposed to vehicle
(VEH) or isoprenaline (ISO), following incubation with a
βAR antagonist or vehicle control (CON). Representative
immunoblots and quantitative data (mean ± SEM) show
the eﬀect of the non-selective βAR antagonist propranolol
(PRO, 100 nM), the β1AR-selective antagonist CGP 20712A
(CGP, 100 nM) and the β2AR-selective antagonist ICI
118,551 (ICI, 100 nM) on the ISO-induced change in B56δ
phosphorylation at S573 (black bars) and cTnI phosphor-
ylation at S23/24 (grey bars). *P < 0.05 vs CON,
✝P < 0.05 vs PRO, ☨P < 0.05 vs CGP (n= 7). B. ARVM
were exposed to VEH or ISO, following incubation with a
PKA inhibitor or CON. Representative immunoblots and
quantitative data (mean ± SEM) show the eﬀect of the
PKA inhibitors H89 (10 μM) and PKI (10 μM) on the ISO-
induced change in B56δ phosphorylation at S573 (black
bars) and cTnI phosphorylation at S23/24 (grey bars).
*P < 0.05 vs CON (n= 4). C. Representative im-
munoblots and quantitative data (mean ± SEM) show the
eﬀect of the PKA-selective analogue of cAMP N6-benzoyl
cAMP (BNZ, 500 μM) and ISO on B56δ phosphorylation at
S573 (black bars) and cTnI phosphorylation at S23/24
(grey bars) (n= 3).
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in ARVM S573 is the only B56δ site that is phosphorylated.
To explore whether ablation of the S573 phosphorylation site im-
pacts on B56δ subcellular localization, we determined the distribution
of GFP-B56δ-WT and GFP-B56δ-S573A in soluble and insoluble com-
partments of fractionated cells. As in earlier experiments (Fig. 3B), the
purity of the soluble and insoluble fractions was conﬁrmed by im-
munoblot analysis of GAPDH and cTnI, respectively (Fig. 4D). Like
endogenous B56δ (Fig. 3B), GFP-B56δ-WT was detected primarily in
the soluble fraction and did not show translocation upon ISO-induced
phosphorylation at S573 (Fig. 4D). The subcellular distribution of GFP-
B56δ-S573A was identical to that of GFP-B56δ-WT, in the absence and
presence of ISO stimulation (Fig. 4D). These ﬁndings indicate that ab-
lation of the S573 phosphorylation site does not impact on the sub-
cellular localization heterologously expressed GFP-B56δ, which
behaves in an analagous manner to endogenous B56δ.
Studies in vitro and in non-cardiac cells have shown that B56δ
phosphorylation at S573 increases the activity of its associated C sub-
unit [16]. To determine the impact of S573 phosphorylation in cardi-
omyocytes, we determined PP2A catalytic activity in lysates of un-
stimulated and ISO-stimulated ARVM expressing GFP, GFP-B56δ-WT or
GFP-B56δ-S573A. PP2A activity was deﬁned as the activity inhibited by
5 nM okadaic acid (OA), a concentration that in vitro is suﬃcient to
inhibit the activity of PP2A but not PP1 [37]. PP2A activity was in-
creased by ISO only in cells expressing GFP-B56δ-WT (Fig. 4E), in-
dicating that B56δ phosphorylation at S573 is necessary for increasing
associated C subunit activity in response to β-adrenergic stimulation.
Fig. 3. Subcellular distribution of B56δ in ARVM. In A and B, ARVM were exposed to vehicle (VEH) or isoprenaline (ISO). A. Fixed and permeabilized cells were incubated with α-actinin
and B56δ primary antibodies. These were detected with Cy3-anti-mouse and Cy5-anti-rabbit secondary antibodies, respectively. Nuclei were stained with DAPI. Representative images
show Cy3-labeled α-actinin (red), Cy5-labeled B56δ (green) and DAPI-stained nuclei (blue) in separate channels. Merged images are also shown. B. Cells lysed in buﬀer containing 1%
Triton-X100 were subjected to subcellular fractionation. Immunoblots show detection of GAPDH (cytosolic protein), H2B (nuclear protein), cTnI (myoﬁlament protein), B56δ and B56α in
soluble (SOL) and insoluble (INSOL) subcellular fractions. Quantitative data (mean ± SEM) show B56δ and B56α abundance in soluble and insoluble fractions. In each experiment,
protein abundance in the ISO group was expressed relative to that in the corresponding VEH group. *P < 0.05 vs VEH (n= 6). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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3.5. The role of S573 phosphorylation in regulation of cardiac protein
phosphorylation
To explore the potential role of B56δ phosphorylation at S573 in β-
adrenergic regulation of cardiac protein phosphorylation, we per-
formed immunoblot analyses of the ARVM phosphoproteome using a
selection of phospho-speciﬁc antibodies detecting phospho-S/T residues
in distinct kinase substrate motifs (Fig. 5). Only a limited number of
ISO-responsive phosphoproteins were detected by these antibodies, and
the intensity of those signals did not diﬀer between cells expressing
GFP-B56δ-WT and those expressing GFP-B56δ-S573A. Of note, the
phospho-speciﬁc antibody recognizing the RRXS/T motif detected
phosphorylation of GFP-B56δ-WT but not GFP-B56δ-S573A (Supple-
mentary Fig. 5), conﬁrming the ability of the method to reveal diﬀer-
ential phosphorylation of S/T residues in abundantly expressed pro-
teins. In complementary experiments, we determined the
phosphorylation status of cTnI, cardiac myosin binding protein-C
(cMyBP-C) and phospholamban (PLB), which are phosphorylated by
PKA following βAR stimulation and play important roles in mediating
inotropic and lusitropic responses. PhosTag SDS/PAGE-immunoblot
analysis of cTnI showed that the abundance of non-phosphorylated
(0P), mono-phosphorylated (1P) and bis-phosphorylated (2P) cTnI was
comparable in cells expressing GFP-B56δ-WT and those expressing GFP-
B56δ-S573A, in the absence or presence of ISO stimulation (Fig. 6A).
Basal and ISO-induced phosphorylation of cMyBP-C at S273, S282 and
S302 (Fig. 6B), and PLB at S16 (Fig. 6C) was also comparable between
cells expressing GFP-B56δ-WT and those expressing GFP-B56δ-S573A.
In complementary experiments, we determined the relative con-
tribution of PP2A versus PP1 activity to the dephosphorylation of cTnI,
cMyBP-C and PLB, by assessing the impact of treatment with OA at a
concentration (100 nM) that selectively inhibits PP2A [38] or at a
higher concentration (1 μM) that also inhibits PP1 [39]. When used at a
PP2A-selective concentration, OA increased the phosphorylation of
both cTnI at S22/23 and cMyBP-C at S282 (Supplementary Fig. 6). In
contrast, PLB phosphorylation at S16 was increased only when PP1 was
also inhibited (Supplementary Fig. 6). The responses to treatment with
diﬀerent concentrations of OA were comparable in ARVM expressing
GFP-B56δ-WT or GFP-B56δ-S573A (Supplementary Fig. 6). These
ﬁndings suggest that PP2A activity is primarily responsible for depho-
sphorylating cTnI at S22/23 and cMyBP-C at S282, with PP1 activity
primarily responsible for dephosphorylating PLB at S16, and ad-
ditionally indicate that those contributions of PP2A versus PP1 activity
are not modiﬁed by ablation of S573 in heterologously expressed GFP-
B56δ.
Fig. 4. Characterization of adenoviral vectors. ARVM
transduced with AdV.GFP, AdV.GFP-B56δ-WT or AdV.GFP-
B56δ-S573A were maintained in culture for 18 h. In C, D
and E, cells were exposed to vehicle (VEH) or isoprenaline
(ISO). A. Expression of PP2AA, PP2AC, B55α, B56α and
B56γ in transduced cells. Quantitative data
(mean ± SEM) show endogenous PP2A subunit expres-
sion normalized to the expression of calsequestrin.
*P < 0.05 vs GFP (n= 3). B. GFP, GFP-B56δ-WT and
GFP-B56δ-S573A were immunoprecipitated from lysates of
transduced cells with a GFP antibody. GFP-B56δ-WT, GFP-
B56δ-S573A, GFP, PP2AA and PP2AC were detected by
immunoblot analysis. C. Phosphorylation of S573 in het-
erologously expressed B56δ. ISO-induced phosphorylation
of S573 in heterologous (GFP-B56δ) and endogenous B56δ
is indicated. D. Cells lysed in buﬀer containing 1% Triton-
X100 were subjected to subcellular fractionation.
Immunoblots show detection of GAPDH, cTnI, GFP-B56δ-
WT and GFP-B56δ-S573A in soluble (SOL) and insoluble
(INSOL) subcellular fractions. The distribution of GFP-
B56δ-WT phosphorylated at S573 is also shown. E. Protein
phosphatase activity was measured in whole cell lysates
using pNPP as substrate. The speciﬁc activity of PP2A was
determined by using 5 nM okadaic acid. Quantitative data
(mean ± SEM) show the ISO-induced change in PP2A
activity. In each experiment, the change in PP2A activity
was expressed as a percentage of the basal activity.
*P < 0.05 vs GFP, ✝P < 0.05 vs SA (n= 6).
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3.6. Expression and phosphorylation of B56δ in mouse models of cardiac
hypertrophy
Finally, to explore whether the phosphorylation and/or the ex-
pression of cardiac B56δ is altered in a pathophysiological setting, we
examined these in a mouse model of pressure overload-induced cardiac
hypertrophy. Seven days post-surgery, heart weight/tibia length was
10.1 ± 0.8 mg/mm in mice subjected to TAC and 7.7 ± 0.2 mg/mm
in mice subjected to sham operation (n = 7, P < 0.05), reﬂecting
cardiac hypertrophy in the former. The abundance of both pS573 B56δ
and total B56δ was increased in the hearts of mice subjected to TAC
relative to mice subjected to sham operation (Fig. 7). These ﬁndings
suggest that, while the relative phosphorylation of B56δ is unaltered,
the absolute abundance of pS573 B56δ is increased in the setting of
pressure overload-induced cardiac hypertrophy.
4. Discussion
The present study has revealed for the ﬁrst time in a cardiac context
that (i) acute simulation of βARs induces a rapid and sustained phos-
phorylation of the PP2A regulatory subunit B56δ selectively at S573,
(ii) this phosphorylation occurs principally through stimulation of the
β1AR and activation of PKA, and (iii) βAR/PKA-mediated phosphor-
ylation of B56δ at S573 increases PP2A activity.
In healthy myocardium, catecholamines regulate a variety of cel-
lular processes primarily by β1AR-mediated activation of protein ki-
nases [40], in particular the Ser/Thr kinases PKA and calcium/calmo-
dulin-dependent kinase II (CaMKII), and the downstream
phosphorylation of PKA and CaMKII substrate proteins [21,22,41,42].
Although the regulation and physiological roles of PKA and CaMKII
have been studied extensively [43–45], knowledge of potential β1AR-
mediated regulation of Ser/Thr phosphatases that serve an opposing
role is restricted largely to type 1 phosphatase (PP1), whose activity is
regulated through PKA-mediated phosphorylation of the PP1-speciﬁc
inhibitor of protein phosphatase-1 (I-1) [46,47]. Nevertheless, members
of the PP2A family are also believed to contribute signiﬁcantly to
myocardial Ser/Thr phosphatase activity and thus dephosphorylation
of functionally important Ser/Thr residues in cardiomyocyte proteins
[30,48–51]. Furthermore, there is emerging evidence for βAR-mediated
regulation of PP2A through it regulatory B subunits, for example
through translocation of the B56α isoform between subcellular com-
partments [29].
Here, we provide robust new evidence that in ARVM the non-se-
lective βAR agonist ISO induces phosphorylation of the PP2A reg-
ulatory subunit isoform B56δ selectively at S573, in a rapid and sus-
tained manner (Fig. 1). Our data with CGP (a selective β1AR antagonist)
and ICI (a selective β2AR antagonist) indicate that the ISO response is
mediated primarily by the β1AR subtype (Fig. 2A). In cells that express
each receptor at similar abundance, the aﬃnity of CGP for the β1AR is
comparable to that of ICI for the β2AR [52]. Importantly, in our ex-
periments, ISO-induced phosphorylation of cTnI at S23/24 (which in
ARVM occurs through the β1AR) [53,54] was also abolished by CGP but
not ICI at a concentration of 100 nM for each agent, indicating eﬀective
blockade of β1AR signaling by the former antagonist. On the basis of
this observation and evidence that in ARVM the relative β1AR:β2AR
abundance is 65:35 [55], it is reasonable to assume that 100 nM ICI was
suﬃcient to block β2AR activation and that its relative ineﬀectiveness
in inhibiting ISO-induced B56δ phosphorylation arose from a minor
role for this βAR subtype in mediating that response.
The data that we have obtained from complementary studies, in
which we explored the role of PKA in mediating B56δ phosphorylation
at S573, indicate that activation of this kinase is both necessary for the
ISO-induced response and suﬃcient per se to induce such phosphor-
ylation. Thus, ISO-induced B56δ phosphorylation was signiﬁcantly at-
tenuated by pre-treatment of ARVM with either H89 or PKI, which
inhibit PKA through distinct mechanisms [56], and selective PKA
Fig. 5. Protein phosphorylation in transduced ARVM. ARVM transduced with AdV.GFP-B56δ-WT or AdV.GFP-B56δ-S573A were maintained in culture for 18 h and exposed to vehicle
(VEH) or isoprenaline (ISO). Immunoblot analysis of the ARVM phosphoproteome was performed with phospho-speciﬁc antibodies detecting phospho-S/T residues in the A. RRXS/T
motif; B. R/KXSXR/L motif; C. RXXS/T motif; and D. LXRXXS/T motif. In each panel, short and long exposures of the ﬁlm to the ECL signal are shown. In A, arrows indicate
phosphorylation of B56δ in GFP-B56δ-WT. L = leucine, R = arginine, S/T = phospho-S/T, Q = glutamine, G = glycine, K = lysine, P = proline, X = any amino acid.
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activation by the cAMP analog BNZ induced B56δ phosphorylation that
was similar in magnitude to that induced by ISO (Fig. 2B and C).
We have shown previously that βAR stimulation by ISO in ARVM
alters the subcellular localisation of another PP2A regulatory subunit
isoform, B56α [29]. Furthermore, in non-cardiac cells, phosphorylation
of B56α has been reported to induce a change in subcellular localisation
of the B56α-PP2A holoenzyme [57]. These ﬁndings prompted us to
explore the possibility that B56δ phosphorylation might impact on the
subcellular localisation of this PP2A regulatory subunit in ARVM.
Nevertheless, there was no marked response to ISO in experiments
utilizing immunolabeling and ﬂuorescent confocal microscopy (which
revealed the spatial distribution of B56δ in intact cells; Fig. 3A) or
cellular fractionation and immunoblot analysis (which revealed the
relative abundance of B56δ in soluble and insoluble fractions; Fig. 3B),
indicating that phosphorylation at S573 does not regulate the sub-
cellular localization of B56δ in ARVM. Furthermore, B56δ was found to
be present throughout the cytosol and nuclei of ARVM (Fig. 3A), which
is consistent with the B56δ distribution reported in rat brain cells [58]
and neuronally diﬀerentiated PC12 cells [19], suggesting that B56δ-
PP2A might target phosphoproteins in multiple subcellular
compartments.
To conﬁrm if S573 is the only B56δ residue that is phosphorylated
downstream of βAR stimulation in a cellular context and to explore
potential functional roles of such phosphorylation, we transduced
ARVM with adenoviruses expressing GFP-tagged B56δ in WT or S573A
mutant form. This work conﬁrmed that, following βAR stimulation,
S573 is the only B56δ residue that exhibits increased phosphorylation,
as detected by a phospho-S/T antibody that targets the optimal PKA
substrate motif (Fig. 4C and Supplementary Fig. 4B). An interesting
observation that arose from the analysis of transduced ARVM was the
approximately 5-fold increase in the expression of endogenous PP2AC
protein that accompanied the heterologous expression of GFP-tagged
B56δ in either form (Fig. 4A). Of note, upregulated PP2AC expression in
response to increased expression of a B56 isoform is not unique to our
present work in isolated ARVM and has been reported previously in
hearts of transgenic mice with cardiac-speciﬁc overexpression of B56α
[10]. Interestingly, expression of endogenous PP2AA protein was un-
changed following heterologous expression of GFP-B56δ-WT or GFP-
B56δ-S573A (Fig. 4A). Thus it appears that in ARVM PP2AC expression
is stringently regulated and increases only when additional regulatory
Fig. 6. Phosphorylation of speciﬁc cardiac phosphoproteins in transduced ARVM. ARVM transduced with AdV.GFP-B56δ-WT or AdV.GFP-B56δ-S573A were maintained in culture for
18 h and exposed to vehicle (VEH) or isoprenaline (ISO). A. Representative immunoblot and quantitative data (mean ± SEM) show abundance of non-phosphorylated (0P), mono-
phosphorylated (1P) and bis-phosphorylated (2P) cTnI. 0P, 1P and 2P cTnI are expressed as a percentage of total cTnI, which is the sum of the signals in each lane. *P < 0.05 vs
corresponding VEH (n= 3). B. Representative immunoblots and quantitative data (mean ± SEM) show phosphorylation of cMyBP-C at S273, S282 and S302. *P < 0.05 vs corre-
sponding VEH (n= 3). C. Representative immunoblots and quantitative data (mean ± SEM) show phosphorylation of PLB at S16. *P < 0.05 vs corresponding VEH (n= 3).
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subunits are available, but there may be an excess pool of PP2AA.
We also explored whether the heterologously expressed of GFP-
tagged B56δ variants formed functional PP2A holoenzyme complexes
with endogenous PP2AC and PP2AA proteins. Analysis of GFP im-
munocomplexes from ARVM expressing GFP-B56δ-WT or GFP-B56δ-
S573A (but not those expressing GFP alone) revealed the presence of
PP2AA and PP2AC proteins in comparable abundance (Fig. 4B), sug-
gesting that the GFP-tagged B56δ variants formed heterotrimeric PP2A
holoenzymes with endogenous scaﬀolding and catalytic subunits. Fur-
thermore, following ISO stimulation, PP2A activity (likely arising lar-
gely from newly formed holoenzyme complexes incorporating the up-
regulated PP2AC subunits) was increased in ARVM expressing GFP-
B56δ-WT but not those expressing GFP-B56δ-S573A (Fig. 4E), in-
dicating that S573 phosphorylation in B56δ is essential for a βAR-
mediated increase in the activity of associated catalytic subunits. This is
consistent with previous observations in non-cardiac cells with diﬀerent
stimuli that also increase cellular PKA activity [16].
Finally, we investigated whether ISO-induced phosphorylation of
cardiomyocyte proteins diﬀered between ARVM expressing GFP-B56δ-
WT versus GFP-B56δ-S573A. Somewhat surprisingly, phospho-speciﬁc
antibodies targeted at phospho-S/T residues residing within distinct
kinase substrate motifs detected only a limited number of phospho-
proteins that displayed altered phosphorylation in response to ISO sti-
mulation, with little apparent diﬀerence between cells expressing GFP-
B56δ-WT or GFP-B56δ-S573A (Fig. 5). The most abundant ISO-re-
sponsive phosphoproteins that were detected migrated at molecular
weights that correspond to those of cTnI, cMyBP-C and PLB, which are
known PKA targets that are phosphorylated in response to βAR sti-
mulation in cardiomyocytes [23,42,59]. Thus, we explored the relative
abundance of non-phosphorylated (0P), mono-phosphorylated (1P) and
bis-phosphorylated (2P) cTnI moieties, and determined the phosphor-
ylation of cMyBP-C and PLB at known phosphoacceptor residues of
established functional importance (S273, S282 and S302 in cMyBP-C;
S16 in PLB). However, in the absence or presence of ISO stimulation,
the phosphorylation proﬁles of cTnI, cMyBP-C and PLB were not dif-
ferent between ARVM expressing GFP-B56δ-WT and those expressing
GFP-B56δ-S573A (Fig. 6). Although these observations may suggest
that the phosphorylation status of S573 in B56δ has no inﬂuence on
βAR-mediated phosphorylation of functionally important phosphopro-
teins, including cTnI, cMyBP-C and PLB, some observations temper such
a conclusion. Firstly, while the heterologously expressed GFP-B56δ-WT
and GFP-B56δ-S573A proteins appeared to form new and functional
PP2A holoenzymes whose activity was regulated in a manner that de-
pended on B56δ phosphorylation at S573, these might not have dis-
placed pre-existing endogenous holoenzymes that are co-localized with
their substrates. Indeed, in ARVM expressing GFP-B56δ-WT or GFP-
B56δ-S573A the abundance and ISO-induced phosphorylation of en-
dogenous B56δ were unaltered (Fig. 4C). Secondly, since the phos-
phospeciﬁc antibodies used detected only a subset of abundantly ex-
pressed phosphoproteins (Fig. 5), our data do not preclude the existence
of other phosphoproteins that are not detected by this approach but are
nevertheless regulated by B56δ-PP2A upon βAR stimulation, in a
manner that is dependent on B56δ phosphorylation at S573. Notably, it
has been proposed that PKA and B56δ-PP2A are co-localized by the
anchoring protein mAKAP, to form a signaling complex that regulates
the phosphorylation and activity of the phosphodiesterase isoform
PDE4D3 and thereby the local concentration of cAMP [60]. Never-
theless, the pertinent evidence was obtained from studies with het-
erologous protein expression in HEK 293 cells, and the physiological
signiﬁcance of this signaling pathway in cardiomyocytes remains to be
conﬁrmed.
With regard to the potential (patho)physiological role(s) of B56δ
phosphorylation, our data from an exploratory analysis of mouse hearts
with pressure overload-induced cardiac hypertrophy show that, while
the relative phosphorylation of B56δ was unaltered, the absolute
abundance of pS573 B56δ was increased signiﬁcantly in that setting.
This change may be a compensatory response to pressure overload-in-
duced cardiac hypertrophy, or play a mechanistic role in its patho-
genesis. Notwithstanding, the dynamic regulation of B56δ phosphor-
ylation and expression in cardiac hypertrophy warrants investigation of
the functional consequences of their targeted manipulation in appro-
priate models. In that context, it is interesting to note also that B56δ
expression has been reported to be increased in dog hearts following
myocardial infarction and in the setting of tachypacing-induced non-
ischemic heart failure [20], although B56δ phosphorylation status was
not determined in that study.
In conclusion, the present study has identiﬁed and characterised a
novel mechanism that is likely to regulate a speciﬁc pool of PP2A ac-
tivity in cardiomyocytes in response to βAR stimulation, through PKA-
mediated phosphorylation of the PP2A regulatory subunit isoform B56δ
at S573. The functional importance of this novel mechanism now re-
quires the establishment of a model system that allows replacement of
endogenous B56δ with a non-phosphorylatable (S573A) mutant (e.g. a
knock-in mouse) and the application of broad-spectrum phosphopro-
teomics analyses, as well the examination of cardiac responses to
(patho)physiological stimuli, in such a model.
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Fig. 7. B56δ regulation in mouse cardiac hypertrophy. Immunoblots and quantitative
data (mean ± SEM) show the abundance of phosphorylated (pS573) and total B56δ in
mouse hearts 7 days after TAC or sham surgery. *P < 0.05 vs sham. (n= 4).
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